Nowadays combining chemotherapeutic drug Paclitaxel (injected) with Lapatinib (oral), a tyrosine kinase inhibitor, has already been used as an effective therapy against breast cancer overexpressing HER2 (Human Epidermal Growth Factor Receptor 2).In addition to improved antitumor effect, toxicity generated mainly from systematic administration of the two drugs is another aspect people concern about.